Clinuvel Pharmaceuticals (ASX:CUV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Clinuvel Pharmaceuticals (ASX:CUV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
CLINUVEL considers Nasdaq listing, ASX delisting
CLINUVEL considers Nasdaq listing and ASX delisting with US headquarters relocation
Investor Presentation
Clinuvel reports FY2026 stable revenues, strong cash reserves, and U.S. expansion plans
Appendix 4G
Corporate Governance Statement
Dividend/Distribution - CUV
Clinuvel declares fully franked AUD 0.05 dividend for FY2026
A decade of profitability provides U.S. expansion foundation
CLINUVEL reports tenth consecutive profit, declares stable dividend, and plans U.S. expansion
Appendix 4E and Annual Report to Shareholders 2026
Clinuvel reports FY2026 results with slight revenue decline, expands U.S. presence, and plans Nasdaq full listing
CLINUVEL Annual Results - Investor Webinar
Becoming a substantial holder
CLINUVEL's injectable peptide platform
Commercial update on vitiligo
CLINUVEL updates on vitiligo treatment landscape and SCENESSE® clinical progress
Update - SCENESSE in vitiligo
Clinuvel updates vitiligo SCENESSE® trials with topline results expected December 2026 and Phase III start in November
Notification of cessation of securities - CUV
CLINUVEL strategic reorganisation to refocus on U.S. markets
CLINUVEL to relocate headquarters to U.S. and refocus operations on U.S. market with workforce reduction
CLINUVEL's ADS commences trading on Nasdaq
CLINUVEL's ADS to commence trading on Nasdaq
SCENESSE approved for EPP in Canada
Health Canada approves SCENESSE® for EPP treatment, expanding CLINUVEL's market
CLINUVEL confirms terms of CEO's Employment Agreement
CLINUVEL publicly files 20-F to U.S. SEC
CLINUVEL files 20-F with SEC to pursue Nasdaq ADS listing upgrade
